Using big data to improve cardiovascular care and outcomes in China: a protocol for the CHinese Electronic health Records Research in Yinzhou (CHERRY) Study

Lin, Hongbo; Tang, Xun; Shen, Peng; Zhang, Dudan; Wu, Jiao; Zhang, Jingyi; Lü, Ping; Si, Yaqin; Gao, Pei

doi:10.1136/bmjopen-2017-019698

Cited by 81 publications

(85 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Detailed methods and data sources used to establish an EHR-based general population-based cohort study in an eastern coastal area of China has been described previously. 17 The control group used in the current study is from the general population to facilitate routine primary care services for local general practitioners (GPs). Since 2009, this regional system has covered nearly all health-related activities of residents within this region, from birth to death, including children, adolescents, pregnant women, adults and elderly people.…”

Section: Population-based Control Groupmentioning

confidence: 99%

Role of Drugs used for chronic disease management on Susceptibility and Severity of COVID-19: A Large Case-Control Study

Yan

Valdes

Vijay

et al. 2020

Preprint

View full text Add to dashboard Cite

Background. Medical editorials have suggested that angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) should not be given to people with arterial hypertension during the coronavirus disease 2019 pandemic because of a potential increased risk of worse clinical outcomes and that calcium channel blockers (CCBs) should be used as an alternative.Methods Using a cohort of 610 COVID-19 cases and 48,667 population-based controls from Zheijang, China we have tested the role of usage of ACEIs, ARBs, CCBs and other medications on risk and severity of COVID 19. Analyses were adjusted for age, sex and BMI and for presence of relevant comorbidities. Findings:Higher BMI, diabetes and cardio/ cerebrovascular disease are independent risk factors for the development of COVID-19. Individuals with hypertension taking CCBs had significantly increased risk [odds ratio (OR)= 1.67 (95% CI 1.2-2.9)) of manifesting symptoms of COVID-19 whereas those taking ARBs and diuretics had significantly lower disease risk (OR=0.24; 95%CI 0.17-0.34 and OR=0.32; 95%CI 0.19-0.57 respectively). Other antihypertensive drugs were not associated with increased . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

show abstract

Section: Population-based Control Groupmentioning

confidence: 99%

Role of Drugs used for chronic disease management on Susceptibility and Severity of COVID-19: A Large Case-Control Study

Yan

Valdes

Vijay

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…In order to harmonize data across multiple sources, decisions must be made on how to combine similar variants of data or duplicative information captured at various timepoints (test ordered, test received, test result) is paramount in a new linkage. Datasets leveraging dozens of individual data sources have been built, however, the full value of a proposed linked dataset will rely heavily on completeness across individual patient‐level observations. Evaluating overlap in terms of population and time, as well as the variable validity and quality, are important for both scientific and operational reasons.…”

Section: Resultsmentioning

confidence: 99%

Linking electronic health data in pharmacoepidemiology: Appropriateness and feasibility

Rivera

Gokhale

Reynolds

et al. 2020

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

Purpose: To provide guidance on data linkage appropriateness and feasibility to plan purposeful and sustainable new linkages that advance pharmacoepidemiology and healthcare research. Planning a new data linkage requires careful evaluation to weigh the resources required with the potential overall benefits. Methods:In response to an International Society for Pharmacoepidemiology (ISPE) call for manuscripts, a working group comprised of members from academic, industry, and government determined priority content areas; appropriateness and feasibility of data linkage was selected. Within this topic, scientific and operational considerations were determined, reviewed, and formulated into key areas, and translated into 12 consensus recommendations.Results: Guidance for feasibility assessment was categorized into five key areas:(1) research objectives and justification; (2) data quality and completeness; (3) the linkage process; (4) data ownership and governance; and (5) overall value added by linkage. Within these key areas, recommendations to consider prior to initiation were developed to evaluate suitability of the linkage to meet research objectives, assess source data completeness and population coverage, and ensure well-defined data governance standards and protections. When creating novel linked datasets, researchers must assess the feasibility of both scientific (data quality and linkage methods) and operational (access, data use and transfer, governance, and cost) aspects. Conclusions:The data linkage feasibility assessment considerations outlined can be used as a guide when designing sustainable linked data resources to generate actionable evidence in healthcare research. These recommendations were constructed for wide applicability and can be adapted depending on the geographic, structural, and data components of the linkage. K E Y W O R D Sdata linkage, feasibility assessment, data methods, big data, healthcare research

show abstract

“…Whereas, the strategy of DRS2 ≥8 followed by FPG ≥5.6 mmol/L had 861 (13.0%) patients free from blood tests and 58 (0.87%) patients free from further OGTT. Considering that many cities in China have established electronic health record systems (eHR), [30][31][32][33] risk assessment based on eHR system may save enormous costs on manpower and materials to identify high-risk population. In this case, combining use of DRS and FPG assay can be used in Chinese adults.…”

Section: Discussionmentioning

confidence: 99%

Performance and costs of multiple screening strategies for type 2 diabetes: two population-based studies in Shanghai, China

Jiang

Cheng

et al. 2020

BMJ Open Diab Res Care

View full text Add to dashboard Cite

IntroductionTo compare the performance and the costs of various assumed screening strategies for type 2 diabetes mellitus (T2DM) among Chinese adults, and identify an optimal one for the population.Research design and methodsTwo multistage-sampling surveys were conducted in Shanghai, China, in 2009 and 2017. All participants were interviewed, had anthropometry, measured fasting plasma glucose (FPG), hemoglobin A1c (A1c) and/or postprandial glucose. The 1999 WHO diagnostic criteria was used to identify undiagnosed T2DM. A previously developed Chinese risk assessment system and a specific risk assessment system developed in this study were applied to calculate diabetes risk score (DRS) 1 and 2. Optimal screening strategies were selected based on the sensitivity, Youden index and the costs using the 2009 survey data as the training set and the 2017 survey data as the validation set. A twofold cross-validation was also performed.ResultsOf numerous assumed strategies, FPG ≥5.6 mmol/L alone performed well (Youden index of 71.8%) and cost least (US$18.4 for each case detected), followed by the strategy of DRS2 ≥8 combining with FPG ≥5.6 mmol/L (Youden index of 71.7% and US$20.2 per case detected) and the strategy of DRS1 ≥17 combining with FPG ≥5.6 mmol/L (Youden index of 72.0% and US$21.6 per case detected). However, FPG alone resulted in more subjects requiring oral glucose tolerance test (OGTT) than did combining with DRS. The strategy of FPG ≥5.6 mmol/L combining with A1c ≥4.7% achieved a Youden index of 72.1%, but had a cost as high as US$48.8 for each case identified. Twofold cross-validation also supported the use of FPG alone, but with an optimal cut-off of 6.1 mmol/L.ConclusionsOur results support the use of FPG alone in T2DM screening in Chinese adults. DRS may be used combining with FPG in populations with available electronic health records to reduce the number of OGTT and save costs of screening.

show abstract

Using big data to improve cardiovascular care and outcomes in China: a protocol for the CHinese Electronic health Records Research in Yinzhou (CHERRY) Study

Cited by 81 publications

References 35 publications

Role of Drugs used for chronic disease management on Susceptibility and Severity of COVID-19: A Large Case-Control Study

Role of Drugs used for chronic disease management on Susceptibility and Severity of COVID-19: A Large Case-Control Study

Linking electronic health data in pharmacoepidemiology: Appropriateness and feasibility

Performance and costs of multiple screening strategies for type 2 diabetes: two population-based studies in Shanghai, China

Contact Info

Product

Resources

About